EP Patent

EP3979985A1 — Compositions and methods for treating central nervous system disorders

Assigned to PaxMedica Inc · Expires 2022-04-13 · 4y expired

What this patent protects

The present invention provides compositions and methods for treating cognitive, social, or behavioral disabilities, and neurodevelopmental disorders such as autism spectrum disorder (ASD) and other central nervous system disorders such as fragile X syndrome (FXS), fragile X-assoc…

USPTO Abstract

The present invention provides compositions and methods for treating cognitive, social, or behavioral disabilities, and neurodevelopmental disorders such as autism spectrum disorder (ASD) and other central nervous system disorders such as fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), chronic fatigue syndrome (CFS), and post-traumatic stress syndrome (PTSD). The present invention provides compositions and methods for the intranasal delivery (IN) of a therapeutically effective amount of an antipurinergic agent such as suramin for treating the disorder in a patient thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3979985A1
Jurisdiction
EP
Classification
Expires
2022-04-13
Drug substance claim
No
Drug product claim
No
Assignee
PaxMedica Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.